BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 36233479)

  • 1. Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit.
    Deharo F; Carvelli J; Cautela J; Garcia M; Sarles C; Maues de Paula A; Bourenne J; Gainnier M; Bichon A
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
    Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
    ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma.
    Xing Q; Zhang ZW; Lin QH; Shen LH; Wang PM; Zhang S; Fan M; Zhu B
    Ann Transl Med; 2020 Mar; 8(5):250. PubMed ID: 32309397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical Features of Myasthenia Gravis as an Immune-related Adverse Event].
    Suzuki S
    Brain Nerve; 2024 Jan; 76(1):27-32. PubMed ID: 38191136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.
    Giovannini E; Bonasoni MP; D'Aleo M; Tamagnini I; Tudini M; Fais P; Pelotti S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade.
    Nelke C; Pawlitzki M; Kerkhoff R; Schroeter CB; Aktas O; Neuen-Jacob E; Polzin A; Meuth SG; Ruck T
    Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):. PubMed ID: 37884388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: A case report.
    Basnet A; Sharma NR; Gautam S; Lamichhane S; Kansakar S; Tiwari K; Pokhrel M; Singh S
    Clin Case Rep; 2024 Jun; 12(6):e8968. PubMed ID: 38863868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
    Vicino A; Hottinger AF; Latifyan S; Boughdad S; Becce F; Prior JO; Kuntzer T; Brouland JP; Dunet V; Obeid M; Théaudin M
    J Neurol; 2024 Apr; 271(4):1947-1958. PubMed ID: 38141128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
    Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
    Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
    Jespersen MS; Fanø S; Stenør C; Møller AK
    Eur Heart J Case Rep; 2021 Nov; 5(11):ytab342. PubMed ID: 34870082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
    Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
    Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
    J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel uses of complement inhibitors in myasthenia gravis-Two case reports.
    Zadeh S; Price H; Drews R; Bouffard MA; Young LH; Narayanaswami P
    Muscle Nerve; 2024 Mar; 69(3):368-372. PubMed ID: 38205840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
    Weaver JM; Dodd K; Knight T; Chaudhri M; Khera R; Lilleker JB; Roberts M; Lorigan P; Cooksley T
    Support Care Cancer; 2023 Aug; 31(9):518. PubMed ID: 37572133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
    Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K
    J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.
    Hyun JW; Kim KH; Kim SH; Kim HJ
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5583-5589. PubMed ID: 36495331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
    Pathak R; Katel A; Massarelli E; Villaflor VM; Sun V; Salgia R
    Oncologist; 2021 Dec; 26(12):1052-1061. PubMed ID: 34378270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of respiratory failure in immune checkpoint inhibitors-induced overlap syndrome: a case series and review of the literature.
    Cuenca JA; Hanmandlu A; Wegner R; Botdorf J; Tummala S; Iliescu CA; Nates JL; Reddy DR
    BMC Anesthesiol; 2023 Sep; 23(1):310. PubMed ID: 37700240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitor-Induced Myositis/Myasthenia Gravis Overlap.
    Gosser C; Al Bawaliz A; Bahaj W; Chesney J; Ranjan S
    Cureus; 2023 Nov; 15(11):e49007. PubMed ID: 38111441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.